GO:0030961 peptidyl-arginine hydroxylation explained

Peptidyl-arginine hydroxylation (GO:0030961) is a biological process in which a hydroxyl group is added to a peptidyl-arginine residue, converting it to peptidyl-hydroxyarginine. This reaction belongs to the wider class of post-translational modifications that remodel the side chains of basic amino acids, and it is catalysed by hydroxylase enzymes that activate molecular oxygen and use reducing cofactors to perform the oxidation. Because arginine is one of the most chemically versatile residues in proteins, its hydroxylation can change hydrogen bonding, charge distribution, and protein-protein interaction surfaces. The process is of growing interest because arginine-modifying enzymes are druggable. Recent medicinal-chemistry work has produced highly potent naphthalene/quinoline-based inhibitors of peptidyl-arginine deiminases (PADs), a related family of arginine-converting enzymes, with detailed structure-activity relationships, selectivity profiles, and cytotoxicity data. These findings establish that enzymes acting on peptidyl-arginine are tractable targets and motivate parallel investigation of hydroxylation as a distinct but mechanistically related modification. For researchers, GO:0030961 matters because it sits at the intersection of enzymology, proteomics, and disease biology. Identifying which proteins carry hydroxyarginine, which enzymes install it, and what phenotypic consequences follow from its loss or gain requires integrated approaches: biochemical assays, mass spectrometry, and CRISPR-based genetic perturbation. This article summarises the definition, mechanism, key genes, disease links, and experimental methods relevant to peptidyl-arginine hydroxylation.

In plain terms, peptidyl-arginine hydroxylation is the addition of an -OH group onto an arginine residue that is already part of a protein chain. The official GO definition states that it is the hydroxylation of peptidyl-arginine to form peptidyl-hydroxyarginine. The substrate is a peptidyl-arginine (arginine within a polypeptide), the product is peptidyl-hydroxyarginine, and the reaction is an oxidative modification catalysed by hydroxylase-type enzymes that require oxygen and reducing equivalents. The term is a biological_process term, meaning it describes a cellular programme or reaction rather than a molecular function or a cellular location. It has no listed synonyms in the source ontology. Because the modification changes the mass of the residue by approximately 16 Da and alters its hydrogen-bonding capacity, it is detectable by high-resolution mass spectrometry and can be studied with site-specific proteomic workflows.

Peptidyl-arginine hydroxylation is important because it expands the chemical repertoire of arginine residues beyond their canonical positive charge and hydrogen-bonding roles, thereby influencing protein structure, interactions, and function. The broader family of arginine-modifying enzymes, including the PADs, has been validated as a therapeutic target class, with potent naphthalene/quinoline-based inhibitors showing selectivity and cytotoxicity in preclinical models. Understanding hydroxylation specifically helps researchers interpret proteomic datasets, design selective inhibitors, and build genetic models that test causality between enzyme activity and disease phenotypes.

The following genes and proteins are relevant to peptidyl-arginine hydroxylation and the broader family of arginine-modifying enzymes, based on published literature on arginine-converting enzymes and their inhibitors.

Regulation of peptidyl-arginine hydroxylation is expected to operate at several levels: enzyme expression, substrate availability, oxygen tension, and redox cofactor supply. Because the reaction consumes molecular oxygen and reducing equivalents, its rate is sensitive to the cellular metabolic state. In the related PAD family, pharmacological regulation with naphthalene/quinoline-based inhibitors has been demonstrated, showing that small molecules can tune arginine-modifying enzyme activity with selectivity and measurable cellular consequences. These findings provide a template for thinking about how hydroxylation might be regulated pharmacologically and genetically.

Arginine-modifying enzymes have attracted attention as drug targets in cancer and inflammatory disease. Potent naphthalene/quinoline-based inhibitors of PAD enzymes show structure-activity relationships, selectivity, and cytotoxicity, indicating that blocking arginine conversion can affect tumour cell viability. Because peptidyl-arginine hydroxylation acts on the same substrate class, it is plausible that dysregulated hydroxylation contributes to similar disease processes, although direct evidence for hydroxylation-specific disease mechanisms remains an active area of research.

Arginine is a central metabolite for immune cells, and enzymes that consume or modify arginine influence immune responses. The broader arginine-modifying enzyme family, including the PADs, has been linked to inflammatory signalling, and inhibitors of these enzymes are being explored for anti-inflammatory applications. Peptidyl-arginine hydroxylation may intersect with these pathways by altering the availability and chemistry of arginine residues in immune-relevant proteins.

The development of highly potent naphthalene/quinoline-based PAD inhibitors demonstrates that the arginine-modifying enzyme class is druggable and that selectivity across family members can be engineered. This precedent supports efforts to discover inhibitors of peptidyl-arginine hydroxylases and to use them as chemical probes to dissect the biological roles of hydroxyarginine in disease models.

Because peptidyl-arginine hydroxylation adds approximately 16 Da to the arginine residue, high-resolution mass spectrometry is the primary method for detecting and mapping the modification. Enrichment workflows and label-free or isotopic labelling strategies can be used to compare wild-type and enzyme-deficient cells, revealing candidate substrate proteins and site occupancy.

Recombinant enzyme preparations can be incubated with peptidyl-arginine substrates in the presence of oxygen and reducing cofactors, and product formation can be monitored by mass spectrometry or chromatographic methods. Such assays are essential for determining kinetic parameters and for testing inhibitors, as illustrated by structure-activity relationship studies on arginine-modifying enzyme inhibitors.

Knockout, point-mutation, and knock-in CRISPR models allow researchers to test whether a candidate enzyme is necessary and sufficient for peptidyl-arginine hydroxylation and for downstream phenotypes. These models complement pharmacological inhibitors and help distinguish on-target from off-target effects.

Cytotoxicity, proliferation, and signalling assays can be used to link enzyme activity to cell behaviour. The cytotoxicity data reported for potent PAD inhibitors provide a template for how phenotypic readouts can be paired with target engagement to validate arginine-modifying enzymes as therapeutic targets.

Researchers studying peptidyl-arginine hydroxylation-related genes often need to determine whether a candidate gene is causally involved in installing the modification, whether a specific catalytic residue is required, and whether gain or loss of activity changes disease-relevant phenotypes. Answering these questions rigorously requires well-controlled genetic models that isolate the enzyme of interest from related family members.

Peptidyl-arginine hydroxylation (GO:0030961) is a biologically meaningful oxidative modification that converts peptidyl-arginine to peptidyl-hydroxyarginine and expands the functional chemistry of arginine residues in proteins. Its study connects enzymology, proteomics, and disease biology, and the broader arginine-modifying enzyme family is already validated as a druggable target class through potent PAD inhibitors. As mass spectrometry and CRISPR technologies mature, researchers are increasingly able to map hydroxyarginine sites, identify the enzymes responsible, and test causality in genetically defined models. These approaches will clarify how peptidyl-arginine hydroxylation contributes to normal physiology and to diseases such as cancer and inflammatory disorders.